    Heino von Prondzynski | Epigenomics AG | ZoomInfo.com 

Heino von Prondzynski's involvement in venture capital (via Quotient Ltd)































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/people/210050-heino-von-prondzynskisection=people&subsection=detail&id=210050




			Search deals by company name, industry, location, investors...			
			




SEARCH


Heinovon ProndzynskiGet alertedif Heino von Prondzynski gets funded!Heino von ProndzynskiQuotient Ltd - DirectorDeals involving Heino von Prondzynski$27,066,500 raised with Quotient Ltd on December, 2014Please note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Some of the profile information was collected using the Crunchbase API. For more details on the profile, please check Heino von Prondzynsk... on Crunchbase.Inaccurate Data? Help us improve WhoGotFunded: post a comment!










 




Heino von Prondzynski: Executive Profile & Biography - Bloomberg









































  





















































































July 29, 2017 5:13 AM ET
Biotechnology

Company Overview of Epigenomics AG



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Heino   von Prondzynski  Chairman of the Supervisory Board , Epigenomics AGAgeTotal Calculated CompensationThis person is connected to 9 Board Members in 9 different organizations across 16 different industries.See Board Relationships68€102,000
Background

		Mr. Heino von Prondzynski served as the Head of Diagnostics Division at Roche Holding AG from 2000 to December 15, 2004. Mr. von Prondzynski served as the Chief Executive Officer of Roche Diagnostics GmbH from December 15, 2004 to January 1, 2006. He served as the Chief Executive Officer of Roche Diagnostics Corporation. Mr. von Prondzynski is an Independent Consultant. He served as a Sales Representative and Marketing Manager of Troponwerke since 1976, General Manager ... of Pharmaceuticals and Diagnostics Business in Austria of Bayer Ltd., since 1986, General Manager of Health Care Sector of Bayer since 1988, General Manager of Bayer Diagnostics since 1994, General Manager and Chief Executive Officer of Chiron Behring GmbH since 1996, General Manager and Chief Executive Officer of Italy since 1997 and President and Head of Vaccines Division at Chiron Vaccines since 1998. From 1996 to 2000, he held several executive positions, including President of Vaccine Business at Chiron Corporation. From 1976 to 1996, he held sales and marketing and general management positions at Bayer A.G. He served as Chief Executive Officer of Bayer do Brasil Healthcare Sector. Mr. von Prondzynski has been Chairman of Supervisory Board at Epigenomics AG since May 2, 2012. He serves as Chairman of Supervisory Board at Henkel Corp. He serves as President of the Supervisory Board at HTL-Strefa S.A. He served as the Chairman of VT Finance AG since April 2008. He served as the Chairman of Nobel Biocare Holding AG from May 2010 to July 3, 2011. He served as a Vice Chairman of VT Finance AG from 2006 to April 2008. Mr. von Prondzynski has been a Lead Independent Director and Director of Quotient Limited since September 2014. He has been a Director of Hospira Inc. since March 2009. He has been a Member of Supervisory Board at Philips New Zealand Limited and Philips Malaysia Sdn. Bhd. since 2007. Mr. von Prondzynski serves as a Member of Supervisory Board at HTL-Strefa S.A. He has been a Member of Supervisory Board at Philips Medical Systems International B.V., Philips Electronics Australia Limited and Koninklijke Philips N.V., since 2007. He serves as a Director of Supervisory Board of Royal Philips, Amsterdam, the Netherlands. He served as a Member of the Management Board of Henkel KGaA from March 1, 2008 to April 14, 2008. He served as a Member of Executive Committee at F. Hoffman-La Roche Ltd., from early 2000 to 2006. He served as a Non-Executive Director of I-MED Holdings Pty Limited since June 12, 2014. Mr. von Prondzynski served as a Member of Supervisory Board at Qiagen NV from 2007 to June 26, 2013. He served as a Director of Caridian BCT, Denver, USA. He served as Independent Director of Tecan Holding AG, Switzerland. He served as a Director of Nobel Biocare Holding AG from March 2010 to July 3, 2011. Mr. von Prondzynski served as a Director of VT Finance AG. He served as a Director of Tecan Group Ltd., until February 2, 2007. He served as a Member of Supervisory Board at Epigenomics AG from May 29, 2007 to March 31, 2010. He is an Honorary Member of Real and Benemerita Sociedade Beneficiencia do Rio de Janeiro and Chairman of the Association of Friends of Einsiedeln Abbey. Mr. von Prondzynski studied Mathematics, Geography and History at Westfälische Wilhelms University of Münster in Germany.Read Full Background




Corporate Headquarters
Geneststrasse 5Berlin, Berlin 10829GermanyPhone: 49 30 243 450Fax: 49 30 2434 5555
Board Members Memberships
2009-PresentIndependent DirectorHospira Inc.2014-PresentLead Independent DirectorQuotient Limited
Education
Unknown/Other Education Westfälische Wilhelms-Universität Münster
Other Affiliations
QIAGEN N.V.Koninklijke Philips N.V.Roche Holding AGPhilips Medical Systems International B.V.Nobel Biocare Holding AGVT Finance AGRoche Diagnostics GmbHRoche Diagnostics CorporationPhilips Malaysia Sdn. Bhd.Philips New Zealand LimitedWestfälische Wilhelms-Universität MünsterTecan Group Ltd.Hospira Inc.Philips Electronics Australia LimitedI-MED Holdings Pty LimitedHTL-STREFA S.A.Quotient Limited


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
Total Annual Cash Compensation€102,000Total Calculated Compensation€102,000




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Epigenomics AG, please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























QTNT Heino von Prondzynski Insider Trades for Quotient Ltd.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Quotient Ltd.

                  NASDAQ: QTNT
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Quotient Ltd.



After Hours
 --Quotes are delayed by 20 min
Jul 28, 2017, 4:30 p.m.


QTNT

/quotes/zigman/30312597/composite


$
5.42




Change

0.00
0.00%

Volume
Volume 1,477
Quotes are delayed by 20 min








/quotes/zigman/30312597/composite
Previous close

$
			5.43
		


$
				5.42
			
Change

-0.01
-0.18%





Day low
Day high
$5.28
$5.72










52 week low
52 week high

            $3.75
        

            $8.64
        


















Insider Activity


Individual




Heino von Prondzynski



Mr. Heino von Prondzynski is Lead Independent Director at Quotient Ltd., Chairman-Supervisory Board at Epigenomics AG, Member-Supervisory Board at Royal Philips NV and Chairman-Supervisory Board at HTL-Strefa SA. He is on the Board of Directors at Quotient Ltd. and Royal Philips NV. Mr. von Prondzynski was previously employed as Chairman by Nobel Biocare Holding AG, Independent Director by Hospira, Inc., Independent Director-Supervisory Board by QIAGEN NV, Chief Executive Officer-Diagnostics Division by F. Hoffmann-La Roche Ltd., Chief Executive Officer by Roche Diagnostics Corp., President-Vaccines Division by Chiron Corp., General Manager by Bayer AG, and General Manager by Bayer SA (Brazil). He also served on the board at BB Medtech AG and CaridianBCT, Inc. He received his undergraduate degree from the University of Münster.



Transactions


Date
Shares
Transaction
Value





10/31/2016
1,291


 
Derivative/Non-derivative trans. at $0 per share.


0


09/04/2016
4,934


 
Derivative/Non-derivative trans. at $0 per share.


0


09/04/2016
12,500


 
Derivative/Non-derivative trans. at $0 per share.


0


09/04/2015
12,500


 
Derivative/Non-derivative trans. at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Paul  Cowan 
Chairman, CEO & Head-Investor Relations




Mr. Edward  Farrell 
Co-President




Mr. Jeremy  Stackawitz 
Co-President




Mr. Christopher J. Lindop 
Chief Financial Officer




Mr. John  Allan 
Chief Technology Officer & Senior Vice President




Mr. Roland W. Boyd 
Treasurer & Controller




Dr. John  Wilkerson 
Independent Director




Mr. Frederick Stanislaus Hallsworth 
Independent Director




Mr. Zubeen  Shroff 
Independent Director




Mr. Brian  McDonough 
Independent Director




Mr. Thomas A. Bologna 
Independent Director




Ms. Sarah A. O'Connor 
Independent Director




Mr. Heino  von Prondzynski 
Lead Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




5:13 AM EDT
July 29, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
5:00a6 insanely cool college classes that will have you longing to hit the books
5:00aBernie Sanders and Larry David are related — and so are these other surprising celebs
12:34aBREAKINGElon Musk details Tesla Model 3 pricing, range
12:21aTesla: Standard Model 3 will cost $35,000, long-range model will cost $44,000
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft


















Quotient Appoints Heino Von Prondzynski To Board Of Directors - TheStreet



































































 

 




















Action Alerts PLUS

Access AAPJim Cramer's Best Stocks for 2017Charitable Trust PortfolioMost Recent Trade Alert25 Investing Rules10 Trading Commandments

Real Money

Access RM25 Rules of InvestingJim Cramer's Best Stocks for 201710 CommandmentsStressed Out StocksCramer's Blog

Cramer
Mad Money
ETFs
Futures
Markets
Much More

BanksBiotechRetailTechPersonal FinanceRetirementFinancial Advisor CenterHow to SpendOptionsFixed IncomeVideo










Privacy Policy|Terms of Use© 1996- TheStreet Inc. All rights reserved
















                                DJIA
                            







                                NASDAQ
                            







                                S&P 500
                            






Market Data updated






Sign In




Your Membership(s)








Your Account





Account Preferences


Alerts


Newsletters







Subscribe





Logout



Subscribe

Access insights and guidance from our Wall Street pros. Find the product that's right for you.
Action Alerts PLUS
Action Alerts OPTIONS
Daily Swing Trade
Income Seeker
Quant Ratings
Real Money
Real Money Pro
Stocks Under $10
Top Stocks
Trifecta Stocks
Real Money Pro Portfolio
Chairman's Club
Compare All 
Chatter on the Street













































 








































Quotient Appoints Heino Von Prondzynski To Board Of Directors






GlobeNewswire



Sep 9, 2014 9:12 AM EDT













 


























































    JERSEY, Channel Islands, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Heino von Prondzynski to the Company's Board of Directors. Mr. von Prondzynski will also serve as the Company's Lead Independent Director. Mr. von Prondzynski brings strong executive management and diverse global experience from leadership positions held at several major multinational healthcare companies.  "I am delighted to announce the appointment of Heino as a Director of Quotient," commented Paul Cowan, Chairman and Chief Executive Officer of Quotient. "He has had a highly distinguished career in the healthcare industry, delivering global growth and profitable expansion. With over 35 years experience in the field of pharmaceuticals, vaccines and medical diagnostics, Heino has shown a keen interest in talent development and a passion for driving product innovation."  Mr. von Prondzynski, 64, served as Chief Executive Officer of Roche Diagnostics and as a member of the Executive Committee of F. Hoffman-La Roche Ltd. from early 2000 to 2006, retiring from Roche at the end of 2006. While at Roche, he brought Roche Diagnostics, which included diabetes, near-patient testing, centralized diagnostics and applied science to global market leadership and record profitability. He also drove significant growth through an expansion of Roche's molecular diagnostics portfolio and entry into the donor-screening market. From 1996 to 2000, Mr. von Prondzynski held several executive positions, including President of the vaccine business at Chiron Corporation, a multinational firm developing biopharmaceuticals, vaccines and blood-testing products. Earlier in his career, Mr. von Prondzynski held sales and marketing and general management positions at Bayer A.G.  Mr. von Prondzynski currently serves on a number of public company boards of directors, including Royal Philips (Netherlands), Hospira Inc. (U.S.A.) and Epigenomics AG (Germany).  About Quotient Limited  Quotient Limited ("Quotient") is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests, currently focused on blood grouping and serological disease screening. Quotient is developing its proprietary MosaiQ TM technology platform to offer a breadth of tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins, Switzerland. CONTACT: Paul Cowan, Chairman & Chief Executive Officer         paul.cowan@quotientbd.com; +41 79 128 6908   



 



 































































 











Trending


FTC Seen as Set to Block Rite Aid Deal


It Would Be 'Crazy' to Clean House at Wells Fargo, CEO Says


Tesaro Resorts to PR Razzle Dazzle to Make Ovarian Cancer Drug Appear Cheaply Priced











Advertising Partners



 






 






 






 


























 

























 































 


©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.




Compare Brokers



 







 







 







 







 







 
















Quotient Appoints Heino von Prondzynski to Board of Directors Nasdaq:QTNT









































































English
Français











Register
Sign In













Quotient Appoints Heino von Prondzynski to Board of Directors




















September 09, 2014 09:12 ET

 | Source: Quotient Limited





JERSEY, Channel Islands, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Quotient Limited (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Heino von Prondzynski to the Company's Board of Directors. Mr. von Prondzynski will also serve as the Company's Lead Independent Director. Mr. von Prondzynski brings strong executive management and diverse global experience from leadership positions held at several major multinational healthcare companies.

	"I am delighted to announce the appointment of Heino as a Director of Quotient," commented Paul Cowan, Chairman and Chief Executive Officer of Quotient. "He has had a highly distinguished career in the healthcare industry, delivering global growth and profitable expansion. With over 35 years experience in the field of pharmaceuticals, vaccines and medical diagnostics, Heino has shown a keen interest in talent development and a passion for driving product innovation."

	Mr. von Prondzynski, 64, served as Chief Executive Officer of Roche Diagnostics and as a member of the Executive Committee of F. Hoffman-La Roche Ltd. from early 2000 to 2006, retiring from Roche at the end of 2006. While at Roche, he brought Roche Diagnostics, which included diabetes, near-patient testing, centralized diagnostics and applied science to global market leadership and record profitability. He also drove significant growth through an expansion of Roche's molecular diagnostics portfolio and entry into the donor-screening market. From 1996 to 2000, Mr. von Prondzynski held several executive positions, including President of the vaccine business at Chiron Corporation, a multinational firm developing biopharmaceuticals, vaccines and blood-testing products. Earlier in his career, Mr. von Prondzynski held sales and marketing and general management positions at Bayer A.G.

	Mr. von Prondzynski currently serves on a number of public company boards of directors, including Royal Philips (Netherlands), Hospira Inc. (U.S.A.) and Epigenomics AG (Germany).

About Quotient Limited

	Quotient Limited ("Quotient") is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests, currently focused on blood grouping and serological disease screening. Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins, Switzerland.
Paul Cowan, Chairman & Chief Executive Officer
paul.cowan@quotientbd.com; +41 79 128 6908



Related Articles
other press releases by Quotient Limited


Quotient Limited to Report Continued Progress on the Commercial Scale-Up of MosaiQ™ and Fiscal First Quarter 2018 Financial Results and Host Conference Call
July 21, 2017 08:00


Quotient Limited to Participate in the Jefferies 2017 Global Healthcare Conference
May 31, 2017 08:00


Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results
May 22, 2017 16:05


Quotient Limited to Participate in the UBS Global Healthcare Conference
May 09, 2017 16:05


Quotient Limited to Report Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call
May 09, 2017 08:00






212



other news releases in

Directors and Officers

in the last 30 days
                            











Profile

Quotient Limited





  Subscribe via RSS
 Subscribe via ATOM
 Javascript



  Newtown, Pennsylvania, UNITED STATES




Contact Data
Paul Cowan, Chairman & Chief Executive Officer
paul.cowan@quotientbd.com; +41 79 128 6908

Contact



With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!



Already have an account?  Log in here.











Media Files



Quotient Limited  Logo






LOGO URL | Copy the link below
            





Formats available:






                            Original
                        




                            Medium
                        




                            Small
                        








Tags
MEDICAL
MANAGEMENT CHANGES














Newswire Distribution Network & Management



Home
Newsroom
RSS Feeds
Legal
Contact Us






About Us
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
            




Contact Us


Corporate Headquarters
2321 Rosecrans Avenue.
Suite 2200
El Segundo, CA 90245
Phone: (800) 307-6627
Fax:  (800) 307-3567
            


European Headquarters
Woolgate Exchange,
25 Basinghall Street,
London EC2V 5HA
UK
Phone: +1 866-465-8454




© 2017 GlobeNewswire, Inc. All Rights Reserved.





